Trial Profile
Phase IV, single centre, randomised, open-label, two-period, two-way crossover clinical trial to assess the efficacy of Bilastine 20mg in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers under fasted and fed conditions.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Bilastine (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms A Wheal and Flare Study
- Sponsors FAES Farma
- 15 Sep 2018 Status changed from recruiting to completed.
- 15 Jun 2018 New trial record